Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Needham Maintains Buy on JFrog, Lowers Price Target to $32

Needham analyst Mike Cikos maintains JFrog (NASDAQ:FROG) with a Buy and lowers the price target from $71 to $32.
byBenzinga Newsdesk
February 9, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Needham analyst Mike Cikos maintains JFrog (NASDAQ:FROG) with a Buy and lowers the price target from $71 to $32.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

FDA Accepted Submission of Supplemental New Drug Application for LYNPARZA in Combination With Abiraterone and Prednisone or Prednisolone for Patients With Metastatic Castration-Resistant Prostate Cancer and Grants Priority Review

By Charles Gross
Today, 11:36 PM
AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that a supplemental New Drug Application (sNDA) for LYNPARZA in combination with abiraterone and prednisone or prednisolone has been accepted and granted priority review by the U.S.

AZN